ECTRIMS 2015 Conference Coverage
Significant differences vs. placebo were maintained over 24 months.
The test can be completed in about one minute and is free to use for clinicians and researchers.
DICAM was strongly linked with expression of ROR-γ, IL-23R, IL-17, IL-22, GM-CSF, and GZMB expression in human CD4+ lymphocytes.
The additional measure of brain volume loss results in a more comprehensive evaluation of disease activity in RRMS.
Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.
Participants also reported a reduction in anxiety and subjective cognitive impairment.
Compared to those who continued smoking, those who stopped experienced a significant decline in the rate of brain volume loss.
The ratio was also predictive of conversion to secondary-progressive MS.
CSF NfL levels were predictive of brain volume loss at first sign of MS and follow-up.
Spinal cord gray matter atrophy was found to be most relevant compared to other conventional MRI metrics.
Compared to RRMS, progressive MS had greater cord atrophy and lesions.
No significant treatment effect on disease progression or brain or cervical spinal atrophy was observed.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics